Business Wire

PA-PROJECT-MANAGEMENT

21.10.2020 15:02:12 CEST | Business Wire | Press release

Share
Project Management Institute Launches Initial Products in Industry’s First Platform-Agnostic Suite of Resources to Accelerate Adoption of Citizen Development at Scale

Project Management Institute (PMI), the world’s leading association for the project management profession, today launched the industry’s first, platform-agnostic educational resources for organizations seeking to implement and scale Citizen Development (CD) practices. The first two products in a planned suite of offerings are available now:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201021005531/en/

  • The PMI Citizen Development Body of Knowledge (CDBOK™) is a centralized resource that will help individuals and enterprises understand best practices for implementing citizen development within an organization at scale.
  • The foundational training course is an e-learning training program that provides an introduction to citizen development and outlines best practices in CD methodologies.

Citizen development platforms use intuitive “low-code” and “no-code” tools, so that even non-technical, non-specialist employees can create apps, software solutions and even enterprise-grade applications without having to learn to code. The emergence of citizen development promises to improve enterprise productivity by making application and software development significantly faster and less costly, while also accelerating value delivery and enabling organizations to achieve outcomes more quickly.

“PMI is ideally positioned to help drive adoption of citizen development,” says Sunil Prashara, PMI President and CEO. “As the world’s leading not-for-profit association for the project management profession, we’ve spent the past 50 years equipping our stakeholders with the most relevant skills and resources so they can deliver change and business value, all to help their organizations succeed. To ensure we are providing the right tools for citizen development, we have tapped leading experts in the field and combined their knowledge and expertise with our own deep experience developing global standards and certification training for project managers all around the world. With more than 600,000 members and 1.5 million gross credential holders in nearly every country, we can serve as an objective resource for organizations and individuals looking to apply citizen development tools and methodologies thoughtfully and with confidence.”

Citizen Development Helps Pave the Way for the Next Wave of Business Transformation

Citizen development should ease the burden on over-taxed IT departments straining to cope with growing demands for support from business units. Forrester Research estimates that by 2024 the U.S. will have a deficit of 500,000 software developers.

“Citizen development will form the next wave of business transformation,” says Mr. Prashara. “Technological advances such as AI are eliminating much of the complexity involved in software development, allowing non-specialists to create their own solutions and bring new products and services to market in unprecedented timeframes. This will democratize software development and turbocharge digital transformation efforts.”

Citizen development enables a “hyper-agile” way of working, which can lead to substantial reductions in cost and development times. With citizen development, the speed at which you can take an idea and design, build, test and deploy apps enables teams and organizations to deliver projects and bring products and services to market faster than ever before.

Scaling Citizen Development at the Enterprise Level, Safely and Securely with PMI

Gartner estimates that the number of active citizen developers will be four times that of professional developers by 2023. PMI’s new suite of products should help facilitate that transition, allowing organizations to promote citizen development among their employees in a measured and secure way.

According to Gartner, 41 percent of business leaders report having active citizen development initiatives underway, with 20 percent either evaluating or planning to start CD initiatives. However, to derive maximum benefit from citizen development, organizations will need to scale it across the enterprise, creating an organizational operating system. There is an urgent need to enable this level of scalability in order to drive transformation efforts, Mr. Prashara says, and that was the driving force behind developing the new PMI offerings.

“PMI recognizes the critical role that citizen development plays in empowering individuals and organizations,” Mr. Prashara says. “As organizations look to leverage citizen development in their digital transformation programs, there are many pitfalls to avoid, including the lack of a comprehensive methodology and framework and adequate training to allow citizen developers to succeed. PMI is addressing this gap by providing a vendor-agnostic framework to support professionals’ need to learn the basics and best practices, but also organizations’ need to unlock the potential of citizen development in compliance with IT governance and security. This will give IT the confidence to scale citizen development across the enterprise to accelerate the organization’s transformation efforts.”

PMI Citizen Developer Products & Experiences in the Pipeline

While the initial offerings are available now, PMI will launch additional PMI Citizen Developer products in the coming months, to include specific role-based courses and certifications, as well as a community portal for sharing CD information and thought leadership. The PMI Citizen Development Body of Knowledge (CDBOK™) will also be followed by an executive book on CD best practices, highlighting specific case studies and leadership perspectives.

To learn how to unlock the potential of citizen development at your organization, go to: pmi.org/citizen-developer .

About Project Management Institute (PMI)

Project Management Institute (PMI) is the world's leading association for those who consider project, program or portfolio management their profession. Through global advocacy, collaboration, education and research, we work to prepare more than three million professionals around the world for The Project Economy: the coming economy in which work, and individuals, are organized around projects, products, programs and value streams. Now 50 years in the making, we work in nearly every country around the world to advance careers, improve organizational success and further mature the project management profession through globally-recognized standards, certifications, communities, resources, tools, academic research, publications, professional development courses and networking opportunities. As part of the PMI family, ProjectManagement.com® interactive website creates online global communities that deliver more resources, better tools, larger networks and broader perspectives. Visit us at www.PMI.org , www.projectmanagement.com , www.facebook.com/PMInstitute and on Twitter @PMInstitute.

Social Media:

https://www.facebook.com/PMInstitute

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release

LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The

“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release

Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the

Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release

Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year

TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release

News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network

Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release

Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye